PA
IBRX icon

Profund Advisors’s ImmunityBio IBRX Stock Holding History

Profund Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Sell
176,503
-66,505
-27% -$503K 0.04% 260
2026
Q1 		$1.86M Buy
243,008
+18,324
+8% +$125K 0.07% 223
2025
Q4 		$445K Buy
224,684
+127,142
+130% +$288K 0.01% 614
2025
Q3 		$240K Buy
97,542
+43,130
+79% +$111K 0.01% 874
2025
Q2 		$144K Sell
54,412
-12,670
-19% -$34.1K 0.01% 945
2025
Q1 		$202K Sell
67,082
-37,102
-36% -$112K 0.01% 901
2024
Q4 		$267K Buy
104,184
+14,960
+17% +$62.3K 0.01% 830
2024
Q3 		$332K Buy
89,224
+9,044
+11% +$41.9K 0.01% 739
2024
Q2 		$507K Sell
80,180
-121,163
-60% -$799K 0.02% 491
2024
Q1 		$1.08M Buy
201,343
+81,386
+68% +$369K 0.04% 340
2023
Q4 		$602K Buy
+119,957
New +$376K 0.03% 458

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Profund Advisors's IBRX Position: Q2 2026 in Review

Profund Advisors reduced its ImmunityBio (IBRX) stake by 27% in Q2 2026, selling an estimated $503K and leaving 176,503 shares worth $1.55M. The position accounts for 0.04% of the portfolio, ranked #260.

Profund Advisors first reported a position in IBRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.86M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Profund Advisors held 176,503 shares of ImmunityBio worth $1.55M as of Q2 2026.
  • Profund Advisors sold 66,505 ImmunityBio shares in Q2 2026, an estimated $503K.
  • ImmunityBio made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #260 holding.
  • Profund Advisors first reported a position in ImmunityBio in Q4 2023 and has held it in 11 quarters since.
  • Profund Advisors's ImmunityBio position peaked at $1.86M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.